pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN
Regeneron UK Limited
Regeneron UK is a pharma organization headquartered in Tarrytown, USA. It trades on NYSE under ticker REGN. Primary therapeutic focus areas include Diabetic Macular Edema, Hypercholesterolemia, Asthma, Macular Degenerati
Phase 2 · small molecule · Obesity
Tirzepatide (MOUNJARO) is a small-molecule subcutaneous therapeutic developed by Regeneron UK Limited for obesity treatment. The program, identified as internal code 18750, is currently in Phase 2 development with a latest milestone dated 6 May 2026. Tirzepatide has already achieved regulatory approval in multiple majo
Internal code 18750
Tirzepatide (MOUNJARO) is a small-molecule subcutaneous therapeutic developed by Regeneron UK Limited for obesity treatment. The program, identified as internal code 18750, is currently in Phase 2 development with a latest milestone dated 6 May 2026. Tirzepatide has already achieved regulatory approval in multiple major markets: the European Union (approved 29 January 2026 by EMA under EMEA/H/C/005620, marketed by Eli Lilly Nederland B.V.), Japan (approved December 2024), and the United States (approved via FDA applications NDA215866 and NDA217806, sponsored by Eli Lilly and Co). The drug is classified within the Alimentary tract and metabolism therapeutic class (A10) and is administered via subcutaneous injection. Despite the Phase 2 designation in this program record, the regulatory approvals across major jurisdictions indicate advanced clinical validation. The obesity indication represents a significant unmet medical need with substantial commercial opportunity. Specific mechanism of action, molecular targets, and detailed trial outcomes remain not yet disclosed in available documentation.
Obesity represents a growing global health burden with limited pharmacological treatment options, creating substantial unmet medical need. The obesity market has expanded significantly following the clinical success of GLP-1 receptor agonists, and tirzepatide enters a competitive but expanding therapeutic landscape. Tirzepatide's approval across the EU, Japan, and US demonstrates regulatory confidence in its efficacy and safety profile for weight management. The subcutaneous administration route aligns with patient preferences established by competing therapies. Commercial significance is substantial given the large addressable patient population and the premium pricing established for obesity therapeutics in developed markets. Tirzepatide's regulatory approvals position it as a meaningful competitor within the obesity treatment space, particularly relevant to healthcare systems and payers evaluating multiple therapeutic options. The Phase 2 program designation suggests ongoing clinical investigation into additional indications, dosing strategies, or patient populations beyond the approved obesity indication. Market relevance is heightened by the demonstrated clinical benefit of dual or multi-target mechanisms in metabolic disease, where tirzepatide may offer differentiation from existing monotherapy approaches. The competitive landscape includes established agents such as SAXENDA (liraglutide, Teva) and multiple diabetes-class medications repurposed for weight management, alongside emerging competitors in the GLP-1 and dual-agonist space.
Drug Class: Alimentary tract and metabolism agent (ATC A10); obesity therapeutic.
Modality: Small molecule.
Route of Administration: Subcutaneous injection.
Mechanism of Action: Not yet disclosed in available documentation.
Molecular Target: Not yet disclosed in available documentation.
Brand Name: MOUNJARO.
International Nonproprietary Name (INN): Tirzepatide.
Related Therapies: Competitive agents in the obesity and metabolic disease space include SAXENDA (liraglutide), FORXIGA (dapagliflozin, AstraZeneca), INVOKANA (canagliflozin, Teva), and multiple other diabetes-class medications. Tirzepatide's regulatory approvals and clinical profile position it within the emerging class of dual or multi-target metabolic agents.
First Approval: United States (FDA, 2023–2024 timeframe per NDA applications); European Union (29 January 2026); Japan (December 2024).
Patent Status: Not yet disclosed in available documentation.
Also known as: obesity, obesity disease
A disorder involving an excessive amount of body fat.
ClinicalTrials.gov lists 50 registered studies for Obesity (Disorder) (AACT aggregate).
Phase breakdown: NA (46), PHASE4 (3), PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0011122), Orphanet — obesity disorder, NCT03412149, NCT06787001, NCT06852391, NCT06881485, NCT06911918, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Japan PMDA Approval
Tirzepatide approved in Japan for obesity indication.
European Union EMA Approval
Tirzepatide approved in the European Union under EMEA/H/C/005620, marketed by Eli Lilly Nederland B.V.
Latest Phase 2 Milestone
Most recent program milestone recorded; specific milestone details not yet disclosed.
Tirzepatide enters a competitive obesity treatment market that includes established and emerging therapies across multiple mechanistic classes. SAXENDA (liraglutide, Teva Pharma GmbH) represents a GLP-1 receptor agonist approved for chronic weight management. Diabetes-class agents with obesity indications include FORXIGA (dapagliflozin, AstraZeneca), a SGLT2 inhibitor; INVOKANA (canagliflozin, Teva), another SGLT2 inhibitor; and multiple dipeptidyl peptidase-4 (DPP-4) inhibitors such as TRAJENTA (linagliptin, Boehringer Ingelheim), ONGLYZA (saxagliptin, AstraZeneca), VIPIDIA (vildagliptin, Takeda), and NESINA (alogliptin, Lacuna Pharma). Additional competitors include ACTOS (pioglitazone, Alphapharm), REPAGLINIDE SUN (repaglinide, Teva), ZYNQUISTA (canagliflozin/metformin, Lexicon), QTRILMET (teneligliptin/metformin, Takeda), and TRAZEC (troglitazone, Teva). Tirzepatide's regulatory approvals across major markets (US, EU, Japan) and its small-molecule, subcutaneous formulation position it as a differentiated option. The competitive advantage likely derives from its mechanism of action and clinical efficacy profile, though specific mechanistic details remain not yet disclosed. The obesity market continues to expand with growing clinical and commercial interest in multi-target agents, positioning tirzepatide within an evolving competitive dynamic.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| TRAJENTA | Boehringer Ingelheim Pty Ltd | — | approved |
| ACTOS | Alphapharm Pty Ltd | — | approved |
| ONGLYZA | AstraZeneca | — | approved |
| VIPIDIA | Takeda | — | approved |
| REPAGLINIDE SUN | Teva Pharma GmbH | — | approved |
| NESINA | Lacuna Pharma Pty Ltd | — | approved |
| ZYNQUISTA | LEXICON PHARMACEUTICALS, INC. | — | approved |
| SAXENDA | Teva Pharma GmbH | — | approved |
| FORXIGA | AstraZeneca | — | approved |
| QTRILMET | Takeda | — | approved |
| TRAZEC | Teva Pharma GmbH | — | approved |
| INVOKANA | Teva Pharma GmbH | — | approved |
| SIBUTRAMINE | — | Monoamine transporter inhibitor | Approved |
| SETMELANOTIDE ACETATE | — | Melanocortin receptor 4 agonist | Approved |
| SETMELANOTIDE | — | Melanocortin receptor 4 agonist | Approved |
| RIMONABANT | — | Cannabinoid CB1 receptor antagonist | Approved |
| PHENTERMINE HYDROCHLORIDE | — | Norepinephrine transporter releasing agent | Approved |
| PHENTERMINE | — | Norepinephrine transporter releasing agent | Approved |
| PHENDIMETRAZINE TARTRATE | — | Norepinephrine transporter inhibitor | Approved |
| ORLISTAT | — | Pancreatic lipase inhibitor | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States (FDA): Tirzepatide approved via two NDA applications: NDA215866 and NDA217806, sponsored by Eli Lilly and Co. Specific approval dates not yet disclosed in available documentation.
European Union (EMA): Tirzepatide approved on 29 January 2026 under EMEA/H/C/005620. Marketing Authorization Holder: Eli Lilly Nederland B.V. Product name: MOUNJARO.
Japan (PMDA): Tirzepatide approved in December 2024 for obesity indication.
China (NMPA): Regulatory status not yet disclosed in available documentation.
Loss of Exclusivity (LOE): Expected LOE date not yet disclosed.
All regulatory approvals are for the obesity indication. Tirzepatide is classified within ATC therapeutic class A10 (Alimentary tract and metabolism). The approval trajectory across three major regulatory jurisdictions within a compressed timeframe reflects regulatory confidence in the clinical and safety profile.
Tirzepatide is approved for the treatment of obesity as a subcutaneous injection. It is classified within the Alimentary tract and metabolism therapeutic class (ATC A10).
Yes, tirzepatide is approved in the United States via FDA applications NDA215866 and NDA217806, sponsored by Eli Lilly and Co. Specific approval dates are not yet disclosed.
Yes, tirzepatide was approved by the European Medicines Agency (EMA) on 29 January 2026 under EMEA/H/C/005620. The Marketing Authorization Holder is Eli Lilly Nederland B.V.
Yes, tirzepatide was approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in December 2024 for obesity treatment.
Tirzepatide is administered as a subcutaneous injection. The specific dosing schedule and injection frequency are not yet disclosed in available documentation.
The specific mechanism of action of tirzepatide is not yet disclosed in available documentation.
The molecular target of tirzepatide is not yet disclosed in available documentation.
Tirzepatide (MOUNJARO) is manufactured and marketed by Eli Lilly and Co globally. Eli Lilly Nederland B.V. holds the Marketing Authorization in the European Union.
Tirzepatide is developed by Regeneron UK Limited as the program sponsor. Eli Lilly and Co is the regulatory sponsor and commercial partner.
Clinical trial NCT06373146 is associated with the tirzepatide program; however, trial design, results, and specific endpoints are not yet disclosed in available documentation.
Tirzepatide is designated as Phase 2 in this program record, with a latest milestone dated 6 May 2026, despite regulatory approvals in the US, EU, and Japan. This suggests ongoing clinical investigation into additional indications or patient populations.
Competitors include SAXENDA (liraglutide, Teva), FORXIGA (dapagliflozin, AstraZeneca), INVOKANA (canagliflozin, Teva), and multiple DPP-4 inhibitors such as TRAJENTA, ONGLYZA, VIPIDIA, and NESINA. The competitive landscape includes both obesity-specific and diabetes-class agents.
The expected loss of exclusivity (LOE) date for tirzepatide is not yet disclosed in available documentation.
Projected peak sales figures are not yet disclosed in available documentation.
No partner is listed in the program record for tirzepatide. The relationship between Regeneron UK Limited (program sponsor) and Eli Lilly and Co (regulatory/commercial partner) suggests a licensing or development agreement, but specific terms are not disclosed.
Patent status and expiration dates for tirzepatide are not yet disclosed in available documentation.
Tirzepatide → Drug → Target → Indication → Company → Trials → Competitors
Strategic Positioning: Tirzepatide's approval across the US, EU, and Japan within a 12–24 month window indicates a coordinated global regulatory strategy by Eli Lilly. The Phase 2 program designation suggests ongoing clinical investigation into additional indications, patient subpopulations, or formulation strategies beyond the approved obesity indication.
Competitive Implications: Tirzepatide enters a market increasingly dominated by GLP-1 receptor agonists and dual-target agents. Its small-molecule, subcutaneous formulation may offer manufacturing and supply-chain advantages over biologics. The competitive landscape is crowded with diabetes-class agents, but tirzepatide's obesity-specific approvals and regulatory trajectory position it as a primary competitor to SAXENDA and emerging dual-agonist therapies.
Future Catalysts: Expected milestones include Phase 2 trial readouts (NCT06373146 status unknown), potential label expansions into related metabolic indications (e.g., type 2 diabetes, cardiovascular outcomes), and geographic expansion into additional markets (China/NMPA status unknown). Commercial uptake will depend on pricing, reimbursement decisions, and clinical differentiation versus GLP-1 agonists.
Unresolved Questions: Mechanism of action, molecular target, and specific Phase 2 trial design remain not yet disclosed. Patent expiration dates and manufacturing scale-up timelines are unknown. The relationship between Regeneron UK Limited (program sponsor) and Eli Lilly and Co (regulatory sponsor/MAH) requires clarification.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.